Skip Navigation


Annals of Oncology Advance Access originally published online on October 14, 2005
Annals of Oncology 2006 17(1):131-134; doi:10.1093/annonc/mdj019
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 3 iss...
Right arrow All Versions of this Article:
17/1/131    most recent
mdj019v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ghavamzadeh, A.
Right arrow Articles by Aghdami, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ghavamzadeh, A.
Right arrow Articles by Aghdami, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy

A. Ghavamzadeh1, K. Alimoghaddam1,*, S. H. Ghaffari1, S. Rostami1, M. Jahani1, R. Hosseini2, A. Mossavi1, E. Baybordi1, A. Khodabadeh1, M. Iravani1, B. Bahar1, Y. Mortazavi3, M. Totonchi1 and N. Aghdami1

1 Haematology, Oncology and BMT Research Centre, Tehran University of Medical Sciences, Tehran; 2 Pharmacology Department of Tehran University of Medical Sciences, Tehran; 3 Department of Haematology of Tarbiat Modaress University, Tehran, Iran

* Correspondence to: Dr K. Alimoghaddam, Haematology, Oncology and BMT Research Centre of Tehran University of Medical Sciences, Shariati Hospital, Kargar Ave., Tehran 14114, Iran. Tel: +98-91-21711635; Fax: +98-21-88004140; E-mail: alimgh{at}ams.ac.ir

Introduction: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear.

Materials and methods: We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT–PCR) on peripheral blood samples.

Results: Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1–57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically.

Conclusions: Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.

Key words: APL, arsenic trioxide, minimal residual disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
Z.-Y. Wang and Z. Chen
Acute promyelocytic leukemia: from highly fatal to highly curable
Blood, March 1, 2008; 111(5): 2505 - 2515.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica, June 1, 2007; 92(6): 753 - 762.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Lo-Coco, E. Ammatuna, and M. A. Sanz
Current treatment of acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 289 - 291.
[Full Text] [PDF]

Home page
 haematolHome page
X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, and M. Ruthardt
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells
Haematologica, March 1, 2007; 92(3): 323 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al.
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol., December 20, 2006; 24(36): 5703 - 5710.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Ghaffari, S Rostami, D Bashash, K Alimoghaddam, and A Ghavamzadeh
Real-time PCR analysis of PML-RAR{alpha} in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy
Ann. Onc., October 1, 2006; 17(10): 1553 - 1559.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. S. Tallman
From rags to riches
Blood, May 1, 2006; 107(9): 3425 - 3425.
[Full Text] [PDF]

Home page
 BloodHome page
D. Douer
ATO: the forefront of APL treatment?
Blood, April 1, 2006; 107(7): 2588 - 2589.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
M. A. Sanz
Treatment of Acute Promyelocytic Leukemia
Hematology, January 1, 2006; 2006(1): 147 - 155.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.